Sparks

Thalia Therapeutics’ H126 results largely reflect a strategic reset, with the company transitioning into a clinical-stage RNA therapeutics business. The key development was the post-period acquisition of Sanmirna Therapeutics in July 2026, which added miRisten (THAT-001), a first-in-class anti-miR-126 therapy in Phase I development for relapsed/refractory acute myeloid leukaemia (AML), to the pipeline. Top-line data from the ongoing Phase I dose-escalation study are targeted for H127, representing the most important near-term value inflection point. Preclinical evidence also supports potential combination development with venetoclax. Thalia highlights miR-126’s high expression in leukaemia stem cells, supporting its potential relevance in treatment resistance and relapse; around 22,000 patients are diagnosed with AML annually in the US, with five-year survival of roughly 33%.

Financially, expenditure increased as the new strategy was implemented, with the operating loss widening to £0.76m from £0.47m. Cash stood at £1.50m at end-June, with a further £1.09m fundraise receivable subsequently collected. The oversubscribed £2.75m placing at 0.6p/share, completed in July alongside the Sanmirna acquisition, is expected to fund the planned work programme through mid-2027, including completion of the miRisten Phase I trial and progression of the cardiovascular programme towards IND-enabling development.

The Sanmirna acquisition materially shifts Thalia from a platform-led story to one with a near-term clinical catalyst, while THAT-002, a dual-acting siRNA targeting PCSK9 and Lp(a), and Nuvec provide additional optionality. The H127 miRisten readout and cash runway beyond mid-2027 are now the key near-term investor considerations.